FDA Reviews Mifepristone Amid GOP Pressure
The Future of Reproductive Healthcare: Navigating the Intersection of FDA Regulation and Political Shifts The landscape of reproductive healthcare is undergoing a seismic shift, moving away from traditional clinic-based models toward a digital-first, medication-heavy approach. At the heart of this evolution lies a complex tug-of-war between federal regulatory agencies, state legislatures, and political activists. As … Read more
